General
Preferred name
LINIFANIB
Synonyms
ABT-869 ()
ABT-869, RG-3635, AL-39324 ()
AL-39324 ()
RG3635 ()
Linifanib (ABT-869) ()
ABT 869 ()
A-741439 ()
RG-3635 ()
AL39324,RG3635 ()
P&D ID
PD003290
CAS
796967-16-3
Tags
available
obsolete probe
drug candidate
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Linifanib is a potent, orally active inhibitor of several receptor tyrosine kinases (RTKs), with principal targets being FLT3, CSF1R and VEGFR2.
(GtoPdb)
DESCRIPTION
inhibitor of VEGFRs
(Informer Set)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
11
Organisms
0
Compound Sets
25
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Obsolete Compounds
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Welcome Trust Cancer Drugs
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
29
Molecular Weight
375.15
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
4
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
4
cLogP
4.9
TPSA
95.83
Fraction CSP3
0.05
Chiral centers
0.0
Largest ring
6.0
QED
0.41
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
FLT1
FLT3
KDR
RTK
KIT
CSF-1R
VEGFR1/FLT1
VEGFR2/KDR
PDGFR??
CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK
RTK inhibitor
CSF1R
c-Fms
c-Kit
PDGFR
VEGFR
Apoptosis related,Autophagy,CSF-1R,FLT3,PDGFR,VEGFR
Compound status
clinical
Pathway
RTK signaling
Angiogenesis
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Apoptosis
Autophagy
Protein Tyrosine Kinase/RTK
Targets
KDR,CSF1R,FLT1,FLT3
MOA
PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Therapeutic Class
Anticancer Agents
Source data
